Growth hormone therapy of turner syndrome

The impact of age of estrogen replacement on final height

Steven D. Chernausek, Kenneth M. Attie, Jose F. Cara, Ron G. Rosenfeld, Jam Frane, G. August, D. Bier, S. Blethen, R. Blizzard, D. Brown, S. Burstein, J. Cara, S. Chernausek, T. Foley, M. Geffner, R. Gotlin, R. Hintz, A. Hollander, S. LaFranchi, B. Lippe & 19 others M. MacGillivray, P. Mahoney, L. Plotnick, A. Rogol, R. Rosenfeld, R. Rosenfield, K. Rubin, P. Saenger, J. Sockalosky, Dennis M Styne, L. Brelsford, D. Brown, L. Frahm, J. Kuntze, A. Johanson, K. Nemo, A. Perlman, B. Sherman, P. Martha

Research output: Contribution to journalArticle

122 Citations (Scopus)

Abstract

Clinical trials of recombinant human GH therapy in Turner syndrome that began more than a decade ago show that GH accelerates the linear growth rate. Several studies indicate that final height is also improved, although the magnitude of the increase has been debated. The age at which feminization is induced could be an important factor in determining the patient's ultimate growth response. To test this, 60 patients from a large (n = 117), previously unreported, clinical trial of GH treatment were randomly assigned to begin conjugated estrogens at either 12 or 15 yr of age. The 60 patients were all less than 11 yr of age at entry (mean, 9.5 yr) and received 0.375 mg/kg·week of GH for nearly 6 yr on a daily or three times weekly regimen. Height gain was calculated by comparing the study patients' final or near final heights to their pretreatment projected heights as well as to those of a separate set of age-matched, historical control patients. Patients in whom estrogen treatment was delayed until age 15 yr gained an average of 8.4 ± 4.3 cm over their projected height, whereas those starting estrogen at 12 yr gained only 5.1 ± 3.6 cm, on the average (P < 0.01). Analysis of the interval data showed that growth was stimulated for approximately 2 yr after estrogen initiation, but then declined in association with bone age advancement. Patients who were older than 11 yr at entry (n = 57) all initiated estrogen 1 yr after beginning GH and showed a mean gain in adult height of 4.7 cm, similar to those given estrogen at age 12 yr. Multivariate analysis revealed that the number of years of GH therapy before estrogen treatment was a strong factor in predicting height gained, indicating that the timing of estrogen introduction is an important determinant of final height in this cohort of GH-treated patients with Turner syndrome matched for baseline age and other characteristics.

Original languageEnglish (US)
Pages (from-to)2439-2445
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume85
Issue number7
DOIs
StatePublished - 2000

Fingerprint

Turner Syndrome
Estrogen Replacement Therapy
Growth Hormone
Estrogens
Therapeutics
Growth
Conjugated (USP) Estrogens
Clinical Trials
Feminization
Bone
Multivariate Analysis
Bone and Bones

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Chernausek, S. D., Attie, K. M., Cara, J. F., Rosenfeld, R. G., Frane, J., August, G., ... Martha, P. (2000). Growth hormone therapy of turner syndrome: The impact of age of estrogen replacement on final height. Journal of Clinical Endocrinology and Metabolism, 85(7), 2439-2445. https://doi.org/10.1210/jc.85.7.2439

Growth hormone therapy of turner syndrome : The impact of age of estrogen replacement on final height. / Chernausek, Steven D.; Attie, Kenneth M.; Cara, Jose F.; Rosenfeld, Ron G.; Frane, Jam; August, G.; Bier, D.; Blethen, S.; Blizzard, R.; Brown, D.; Burstein, S.; Cara, J.; Chernausek, S.; Foley, T.; Geffner, M.; Gotlin, R.; Hintz, R.; Hollander, A.; LaFranchi, S.; Lippe, B.; MacGillivray, M.; Mahoney, P.; Plotnick, L.; Rogol, A.; Rosenfeld, R.; Rosenfield, R.; Rubin, K.; Saenger, P.; Sockalosky, J.; Styne, Dennis M; Brelsford, L.; Brown, D.; Frahm, L.; Kuntze, J.; Johanson, A.; Nemo, K.; Perlman, A.; Sherman, B.; Martha, P.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 85, No. 7, 2000, p. 2439-2445.

Research output: Contribution to journalArticle

Chernausek, SD, Attie, KM, Cara, JF, Rosenfeld, RG, Frane, J, August, G, Bier, D, Blethen, S, Blizzard, R, Brown, D, Burstein, S, Cara, J, Chernausek, S, Foley, T, Geffner, M, Gotlin, R, Hintz, R, Hollander, A, LaFranchi, S, Lippe, B, MacGillivray, M, Mahoney, P, Plotnick, L, Rogol, A, Rosenfeld, R, Rosenfield, R, Rubin, K, Saenger, P, Sockalosky, J, Styne, DM, Brelsford, L, Brown, D, Frahm, L, Kuntze, J, Johanson, A, Nemo, K, Perlman, A, Sherman, B & Martha, P 2000, 'Growth hormone therapy of turner syndrome: The impact of age of estrogen replacement on final height', Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 7, pp. 2439-2445. https://doi.org/10.1210/jc.85.7.2439
Chernausek, Steven D. ; Attie, Kenneth M. ; Cara, Jose F. ; Rosenfeld, Ron G. ; Frane, Jam ; August, G. ; Bier, D. ; Blethen, S. ; Blizzard, R. ; Brown, D. ; Burstein, S. ; Cara, J. ; Chernausek, S. ; Foley, T. ; Geffner, M. ; Gotlin, R. ; Hintz, R. ; Hollander, A. ; LaFranchi, S. ; Lippe, B. ; MacGillivray, M. ; Mahoney, P. ; Plotnick, L. ; Rogol, A. ; Rosenfeld, R. ; Rosenfield, R. ; Rubin, K. ; Saenger, P. ; Sockalosky, J. ; Styne, Dennis M ; Brelsford, L. ; Brown, D. ; Frahm, L. ; Kuntze, J. ; Johanson, A. ; Nemo, K. ; Perlman, A. ; Sherman, B. ; Martha, P. / Growth hormone therapy of turner syndrome : The impact of age of estrogen replacement on final height. In: Journal of Clinical Endocrinology and Metabolism. 2000 ; Vol. 85, No. 7. pp. 2439-2445.
@article{f173458d604a47019d49506609a6a6a5,
title = "Growth hormone therapy of turner syndrome: The impact of age of estrogen replacement on final height",
abstract = "Clinical trials of recombinant human GH therapy in Turner syndrome that began more than a decade ago show that GH accelerates the linear growth rate. Several studies indicate that final height is also improved, although the magnitude of the increase has been debated. The age at which feminization is induced could be an important factor in determining the patient's ultimate growth response. To test this, 60 patients from a large (n = 117), previously unreported, clinical trial of GH treatment were randomly assigned to begin conjugated estrogens at either 12 or 15 yr of age. The 60 patients were all less than 11 yr of age at entry (mean, 9.5 yr) and received 0.375 mg/kg·week of GH for nearly 6 yr on a daily or three times weekly regimen. Height gain was calculated by comparing the study patients' final or near final heights to their pretreatment projected heights as well as to those of a separate set of age-matched, historical control patients. Patients in whom estrogen treatment was delayed until age 15 yr gained an average of 8.4 ± 4.3 cm over their projected height, whereas those starting estrogen at 12 yr gained only 5.1 ± 3.6 cm, on the average (P < 0.01). Analysis of the interval data showed that growth was stimulated for approximately 2 yr after estrogen initiation, but then declined in association with bone age advancement. Patients who were older than 11 yr at entry (n = 57) all initiated estrogen 1 yr after beginning GH and showed a mean gain in adult height of 4.7 cm, similar to those given estrogen at age 12 yr. Multivariate analysis revealed that the number of years of GH therapy before estrogen treatment was a strong factor in predicting height gained, indicating that the timing of estrogen introduction is an important determinant of final height in this cohort of GH-treated patients with Turner syndrome matched for baseline age and other characteristics.",
author = "Chernausek, {Steven D.} and Attie, {Kenneth M.} and Cara, {Jose F.} and Rosenfeld, {Ron G.} and Jam Frane and G. August and D. Bier and S. Blethen and R. Blizzard and D. Brown and S. Burstein and J. Cara and S. Chernausek and T. Foley and M. Geffner and R. Gotlin and R. Hintz and A. Hollander and S. LaFranchi and B. Lippe and M. MacGillivray and P. Mahoney and L. Plotnick and A. Rogol and R. Rosenfeld and R. Rosenfield and K. Rubin and P. Saenger and J. Sockalosky and Styne, {Dennis M} and L. Brelsford and D. Brown and L. Frahm and J. Kuntze and A. Johanson and K. Nemo and A. Perlman and B. Sherman and P. Martha",
year = "2000",
doi = "10.1210/jc.85.7.2439",
language = "English (US)",
volume = "85",
pages = "2439--2445",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "7",

}

TY - JOUR

T1 - Growth hormone therapy of turner syndrome

T2 - The impact of age of estrogen replacement on final height

AU - Chernausek, Steven D.

AU - Attie, Kenneth M.

AU - Cara, Jose F.

AU - Rosenfeld, Ron G.

AU - Frane, Jam

AU - August, G.

AU - Bier, D.

AU - Blethen, S.

AU - Blizzard, R.

AU - Brown, D.

AU - Burstein, S.

AU - Cara, J.

AU - Chernausek, S.

AU - Foley, T.

AU - Geffner, M.

AU - Gotlin, R.

AU - Hintz, R.

AU - Hollander, A.

AU - LaFranchi, S.

AU - Lippe, B.

AU - MacGillivray, M.

AU - Mahoney, P.

AU - Plotnick, L.

AU - Rogol, A.

AU - Rosenfeld, R.

AU - Rosenfield, R.

AU - Rubin, K.

AU - Saenger, P.

AU - Sockalosky, J.

AU - Styne, Dennis M

AU - Brelsford, L.

AU - Brown, D.

AU - Frahm, L.

AU - Kuntze, J.

AU - Johanson, A.

AU - Nemo, K.

AU - Perlman, A.

AU - Sherman, B.

AU - Martha, P.

PY - 2000

Y1 - 2000

N2 - Clinical trials of recombinant human GH therapy in Turner syndrome that began more than a decade ago show that GH accelerates the linear growth rate. Several studies indicate that final height is also improved, although the magnitude of the increase has been debated. The age at which feminization is induced could be an important factor in determining the patient's ultimate growth response. To test this, 60 patients from a large (n = 117), previously unreported, clinical trial of GH treatment were randomly assigned to begin conjugated estrogens at either 12 or 15 yr of age. The 60 patients were all less than 11 yr of age at entry (mean, 9.5 yr) and received 0.375 mg/kg·week of GH for nearly 6 yr on a daily or three times weekly regimen. Height gain was calculated by comparing the study patients' final or near final heights to their pretreatment projected heights as well as to those of a separate set of age-matched, historical control patients. Patients in whom estrogen treatment was delayed until age 15 yr gained an average of 8.4 ± 4.3 cm over their projected height, whereas those starting estrogen at 12 yr gained only 5.1 ± 3.6 cm, on the average (P < 0.01). Analysis of the interval data showed that growth was stimulated for approximately 2 yr after estrogen initiation, but then declined in association with bone age advancement. Patients who were older than 11 yr at entry (n = 57) all initiated estrogen 1 yr after beginning GH and showed a mean gain in adult height of 4.7 cm, similar to those given estrogen at age 12 yr. Multivariate analysis revealed that the number of years of GH therapy before estrogen treatment was a strong factor in predicting height gained, indicating that the timing of estrogen introduction is an important determinant of final height in this cohort of GH-treated patients with Turner syndrome matched for baseline age and other characteristics.

AB - Clinical trials of recombinant human GH therapy in Turner syndrome that began more than a decade ago show that GH accelerates the linear growth rate. Several studies indicate that final height is also improved, although the magnitude of the increase has been debated. The age at which feminization is induced could be an important factor in determining the patient's ultimate growth response. To test this, 60 patients from a large (n = 117), previously unreported, clinical trial of GH treatment were randomly assigned to begin conjugated estrogens at either 12 or 15 yr of age. The 60 patients were all less than 11 yr of age at entry (mean, 9.5 yr) and received 0.375 mg/kg·week of GH for nearly 6 yr on a daily or three times weekly regimen. Height gain was calculated by comparing the study patients' final or near final heights to their pretreatment projected heights as well as to those of a separate set of age-matched, historical control patients. Patients in whom estrogen treatment was delayed until age 15 yr gained an average of 8.4 ± 4.3 cm over their projected height, whereas those starting estrogen at 12 yr gained only 5.1 ± 3.6 cm, on the average (P < 0.01). Analysis of the interval data showed that growth was stimulated for approximately 2 yr after estrogen initiation, but then declined in association with bone age advancement. Patients who were older than 11 yr at entry (n = 57) all initiated estrogen 1 yr after beginning GH and showed a mean gain in adult height of 4.7 cm, similar to those given estrogen at age 12 yr. Multivariate analysis revealed that the number of years of GH therapy before estrogen treatment was a strong factor in predicting height gained, indicating that the timing of estrogen introduction is an important determinant of final height in this cohort of GH-treated patients with Turner syndrome matched for baseline age and other characteristics.

UR - http://www.scopus.com/inward/record.url?scp=0034457376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034457376&partnerID=8YFLogxK

U2 - 10.1210/jc.85.7.2439

DO - 10.1210/jc.85.7.2439

M3 - Article

VL - 85

SP - 2439

EP - 2445

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 7

ER -